Home / Health / Covishield shows 60-70% efficacy; Modi to visit Serum Institute on Saturday

Covishield shows 60-70% efficacy; Modi to visit Serum Institute on Saturday

SII is unlikely to announce any interim data from the trials here. It will wait to compile and analyse data, before sharing it with the Indian regulator.

Premium

Oxford and AstraZeneca are also expected to submit their global trial data to the Indian drug regulator, with people in the know indicating that recent developments will not delay the timeline.

Sohini Das Bloomberg Mumbai

3 min read Last Updated : Nov 26 2020 | 11:40 PM IST

Interim data from the Indian arm of Oxford-AstraZeneca vaccine candidate AZD1222 (also known as Covishield) has shown the lowest efficacy results of 60-70 per cent. Pune-based Serum Institute of India (SII) is conducting phase-3 trials on 1,600 Indian volunteers, with people in the know indicating that these trials are being done with two full doses. So far, they added, trials have shown efficacy of 60-70 per cent. If the primer-booster regimen (half dose followed by a full dose) has to be adopted, SII would need to conduct additional tests.

On the Oxford-AstraZeneca vaccine, an SII spokesperson said: “The AstraZeneca-Oxford vaccine is

Topics : Coronavirus Vaccine Narendra Modi Serum Institute of India

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in